Abiologics, a Flagship Pioneering company, has launched to develop a new class of supranatural and programmable medicines called Synteins. Synteins are computationally-generated and synthesised with novel building blocks, potentially providing treatments across a wide range of diseases. Flagship has initially committed $50 million to advance the company’s platform and develop a diverse pipeline of medicines, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!